Aims: Acquired Von Willebrand syndrome (AVWS) is an acquired bleeding disorder that has been reported to aggravate bleeding complications in patients with ventricular assist devices or aortic stenosis. AVWS is characterized by the loss of the high-molecular-weight (HMW) multimers of Von Willebrand factor (VWF) with consequent impaired VWF binding to platelets and collagen. The aim of this study was to investigate the development of AVWS in patients treated with veno-venous ECMO (extracorporeal membrane oxygenation) support. Methods: We examined the presence of AVWS in adult patients receiving ECMO support (n 18) and control subjects treated without ECMO support (n 18). The diagnosis of AVWS was made based on the ratio of collagen-binding capacity to VWF-antigen (VWF:CB/VWF:Ag) and a VWF multimeric analysis. In addition, bleeding episodes were monitored. Results: All patients supported with ECMO developed AVWS. AVWS was identified in the early period after ECMO implantation, i.e. within 24 hours after ECMO implantation. In 17 patients, the VWF:CB/VWF:Ag ratio was significantly reduced and HMW multimers were severely missing, and 17 of the 18 patients developed bleeding complications and required transfusions of blood, FFP and/ or platelet concentrates. In addition, nine patients without an ECMO device were investigated (prior to ECMO implantation: n 2, after ECMO explantation: n 7). Conclusions: In this study, all patients treated with ECMO support developed AVWS, and AVWS was detectable within 24 hours after ECMO implantation. However, the AVWS was reversible after ECMO explantation. Making an early diagnosis of AVWS and providing appropriate treatment may reduce the incidence of life-threatening bleeding. 
required for this retrospective and anonymous analysis. Patients treated with veno-venous ECMO support (n 18, Table 1A ) and healthy controls treated without ECMO support (n 18, Table 1B) were analyzed. The ECMO patients were connected to the extracorporeal system using either two single-lumen HLS ® -catheters (Maquet Holding GmbH & Co. KG, Rastatt, Germany) or a transjugular two-stage Avalon Elite ® -catheter (Avalon Laboratories, Rancho Dominguez, California, USA). In one patient, a NovaPort Twin ® -cannula (Novalung GmbH, Heilbronn, Germany) was inserted. A Revolution ® -centrifugal pump (Sorin Group, Mirandola, Italy) and either EOS ® -(Sorin Group, Mirandola, Italy) or Hilite ® -Oxygenators (Medos Medizintechnik AG, Stolberg, Germany) were used. In addition, the patients received either the continuous infusion of unfractionated heparin with an aPTT target of 40-50 seconds or the subcutaneous injection of low-molecular-weight heparin.
A total of 18 patients were analyzed after ECMO implantation at the medical center of the University of Freiburg between December 2009 and April 2014. Two of these 18 patients treated with ECMO devices were analyzed prior to ECMO implantation, eight patients were assessed during the course of ECMO support and seven patients were evaluated after ECMO explantation (Table 2 ). In addition, bleeding episodes were monitored in all 18 patients. The anonymous use of data was approved by the institutional ethics committee.
Laboratory Analysis
Sodium citrate plasma was obtained via centrifugation at 1,500 g for 15 minutes at 20 and analyzed within four hours after blood collection or stored at 80 . The VWF antibody (Fa. DAKO, Hamburg, Germany) was immobilized on a microtiter plate, and the VWF:antigen (VW:Ag) in the plasma was analyzed photometrically using an enzyme-linked immunosorbent assay (ELISA). Collagen type 1 (Nycomed Pharma, Unterschleissheim, Germany) was immobilized on a microtiter plate, and the collagen-binding capacity (VWF:CB) in the plasma was determined photometrically using the enzyme-linked immunosorbent assay (ELISA) technique. In addition, we calculated the ratio of VWF:CB to VWF:Ag (VWF:CB/ VWF:Ag, normal: 0.7). These values reflect the biological activity of the available VWF with regard to binding to collagen 12) . VWF multimers were separated on sodium dodecylsulfate (SDS)-agarose low-resolution gels (1.0% agarose) and blotted on a poly (vinylidene fluoride) (PVDF) membrane to assess the HMW multim-
Introduction
ECMO devices support patients with potentially reversible respiratory or cardiac failure who are unresponsive to maximal conventional therapy. There are two types of ECMO: veno-venous ECMO for respiratory failure and veno-arterial ECMO for cardiac and respiratory failure. Frequent bleeding episodes have been described as a serious complication in patients treated with veno-venous ECMO support [1] [2] [3] . Such patients suffer from epistaxis and gastrointestinal and/ or intracranial hemorrhage. Veno-venous ECMO is commonly used as a bridging procedure in patients listed for lung transplantation; hemorrhagic diathesis is a complication of peri-and intraoperative care in these patients. The reasons for the increased rate of bleeding symptoms in patients receiving ECMO have not been clarified to date. Acquired Von Willebrand syndrome (AVWS) has been described to increase the risk of bleeding complications in patients treated with ventricular assist devices (VADs) [4] [5] [6] [7] [8] . AVWS results from increased shear stress in VADs and the tubes that connect the VAD to the heart and great vessels. Artificial surfaces and differences in velocity may enhance shear stress, which subsequently leads to the unfolding of Von Willebrand factor (VWF) and cleavage by the protease ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin motif ) [9] [10] [11] . This process induces the loss of high-molecular weight (HMW) multimers, thus resulting in the decreased binding of VWF to collagen. Therefore, we hypothesized that the increased bleeding symptoms observed in patients treated with veno-venous ECMO support may be caused by AVWS and thus investigated whether patients develop AVWS after ECMO implantation. In addition, we analyzed the time of onset of AVWS after ECMO implantation in two patients and examined whether AVWS can be reversed after ECMO explantation (n 7).
Materials and Methods
The study was approved by the ethics committee of Albert-Ludwigs University, Freiburg. According to the vote of the committee, informed consent was not Eschborn, Germany) was used for the control samples. AVWS was diagnosed if the HMW multimers were missing and the VWF:CB/VWF:Ag ratio was below the normal range 13, 10) . The INR (international normalized ratio, Innoers. VWF was detected using the appropriate primary and secondary antibodies (DAKO, Hamburg, Germany) and stained with 3,30-diaminobenzidin/cobalt chloride (Bio-Rad, Munich, Germany). Standard human plasma (Siemens Healthcare Diagnostics, in the ECMO group. The Mann-Whitney U-test was employed for comparisons of unpaired data.
Results
The VWF:CB/VWF:Ag ratios were reduced in all patients treated with ECMO support (in one patient, the ratio was only slightly reduced) (Fig. 1A) . In contrast, the VWF:antigen ratio was increased in all patients receiving ECMO support, whereas the VWF:CB values (which reflect VWF binding to collagen) were much lower than the VWF:antigen values, thus resulting in low VWF:CB/VWF:Ag ratios.
vin Siemens Healthcare Diagnostics, Eschborn, Germany), prothrombin time (PT) (Siemens Healthcare Diagnostics, Eschborn, Germany), activated partial thromboplastin time (aPTT) (Pathromtin SLW, Siemens Healthcare Diagnostics, Eschborn, Germany), hemoglobin (Hb) level, hematocrit (Hk) level and platelet count were also analyzed.
Statistical Analysis
The statistical analyses were performed using the IBM SPSS statistics Version 22 software program for all calculations. The Wilcoxon signed-rank test was applied to the values obtained at different time points Most episodes of bleeding were diffuse and appeared as spontaneous hemorrhage at mucosal, bronchial or puncture sites. Local hemostyptic therapy with epinephrine lavage, oxycellulose gauze or compression bandages was applied in 17 patients. Two Accordingly, high molecular multimers were missing in all (except one) patients treated with ECMO support, leading to a diagnosis AVWS. Fig. 1B illustrates the absence of VWF HMW multimers in a patient treated with ECMO support. The loss of HMW multimers was borderline in only one patient who also exhibited a slightly reduced VWF:CB/VWF:Ag ratio. Compared to the pre-ECMO values, the VWF:CB/ VWF:Ag ratios decreased after ECMO implantation (Fig. 2) . All control subjects with normal values for VWF:CB/VWF:Ag also had normal HMW multimers. The onset of AVWS was quick; the VWF:CB/ VWF:Ag ratio decreased and the HMW multimers were found to be missing within 24 hours after ECMO exposure. AVWS was also detected during the further course of treatment in all eight ECMO patients tested (n 8).
Remarkably, AVWS was reversible after ECMO explantation; the VWF:CB/VWF:Ag ratio normalized and the HMW multimers again became detectable (Fig. 3A and Fig. 3B ). In addition, most patients treated with veno-venous ECMO support displayed normal values for the prothrombin time (PT) and INR, with slightly reduced PT and increased INR values in only four of the 18 patients. Furthermore, the activated partial thromboplastin time (aPTT) was slightly prolonged in most of the ECMO patients (15/18) due to the effects of anticoagulation with heparin. pared to that noted on surfaces with a lower grade of roughness 20) , and coating artificial surfaces with swellable polymers has the potential to minimize platelet activation in perfusion models 21) . The extent of AVWS appears to be more pronounced in patients with ECMO and VAD than in those with aortic stenosis. Among patients with aortic stenosis, pathologic ratios have been reported in only five of 10 and three of 10 patients 13) , whereas AVWS was detectable in all of our ECMO (except for one patient who showed borderline values) and VAD patients. Previous investigations have demonstrated that the onset of AVWS is usually fast (within 24 hours after VAD exposure) 18) . In addition, the onset of AVWS was within 24 hours in the two investigated ECMO patients in this study. Prior to ECMO implantation, the tested patients did not exhibit any signs of AVWS.
Our group previously demonstrated the reversal of AVWS following explantation of the VAD 5) . The present findings also showed that AVWS is reversible in ECMO patients after ECMO explantation, as this phenomenon was observed in both the patients with VAD and aortic stenosis.
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The authors declare no conflicts of interest. patients required continuous lavage of the urinary bladder following the onset of macrohematuria. Gastroscopy was performed in one patient due to active gastric bleeding. In that case, hemorrhagic gastritis was identified without a specific source of bleeding; therefore, local therapy was not applicable. Hematochezia was reported in two patients, and emergency listing for lung transplantation was rejected due to relevant bleeding diathesis in one patient.
Discussion
Impaired coagulation due to the use of venovenous ECMO support is reflected by a decreased collagen binding capacity to VWF antigens in our 18 ECMO patients. Pathological collagen binding and the lack of high-molecular-weight VWF multimers were found in all ECMO patients (one patient's values were only mildly reduced). As expected, the collagen binding ratio and VWF multimers were normal in all 18 control subjects. The increased rate of bleeding symptoms after ECMO implantation may be explained by the onset of AVWS. To date, the development of AVWS in patients with ECMO has not been reported.
Among the patients tested before vvECMO implantation to treat respiratory failure, normal values for the VWF:antigen and VWF:CB/VWF:Ag ratios and VWF-HMW multimers were found. This is in contrast to that observed in patients with acute cardiac failure, in whom the VWF:Antigen and VWF-HMW multimer concentrations are increased for up to 14 days 14, 15) . Due to increased VWF release from endothelial cells in the acute phase (ECMO implantation and stress), the VWF:antigen values are also increased in patients treated with ECMO support, although the function of VWF is impaired. Gastrointestinal bleeding has been reported in patients with aortic stenosis and VAD and appears to be caused by AVWS. Enhanced shear stress at the site of the stenotic valve or in the VAD results in the mechanical destruction of large multimers. As observed in the setting of VAD [16] [17] [18] [19] and cases of aortic stenosis, flow acceleration may be a cause of shear stress in patients treated with ECMO devices, subsequently leading to AVWS.
In addition to shear stress, the configuration of the artificial surface of the extracorporeal system appears to play an important role in the activation of platelets and consumption of VWF-HMW multimers. The higher degree of roughness of impeller pumps, for example, results in increased adhesion of VWF and fibrinogen on the artificial surface com-
